Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review
1
Edmond J. Safra Program in Parkinson’s Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON M5T2S8, Canada
2
Division of Neurology, University of Toronto, Toronto, ON M5S 3H2, Canada
3
Krembil Brain Institute, Toronto, ON M5T 1M8, Canada
4
Lawson Health Research Institute, London, ON N6A 4V2, Canada
*
Author to whom correspondence should be addressed.
Toxins 2020, 12(8), 470; https://doi.org/10.3390/toxins12080470
Received: 6 June 2020 / Revised: 9 July 2020 / Accepted: 11 July 2020 / Published: 24 July 2020
(This article belongs to the Special Issue Botulinum Toxin for the Treatment of Neurological Disorders—Where We Are and Where We Need to Go)
Cervical dystonia (CD) is a neurological movement disorder characterized by sustained involuntary muscle contractions. First-line therapy for CD is intramuscular injections of botulinum neurotoxin (e.g., abobotulinumtoxinA) into the affected muscles. The objective of this systematic literature review is to assess the clinical evidence regarding the effects of abobotulinumtoxinA for treatment of CD in studies of safety, efficacy, patient-reported outcomes, and economic outcomes. Using comprehensive electronic medical literature databases, a search strategy was developed using a combination of Medical Subject Heading terms and keywords. Results were reviewed by two independent reviewers who rated the level of evidence. The search yielded 263 publications, of which 232 were excluded for being duplicate publications, not meeting the selection criteria, or failing to meet predefined eligibility criteria, leaving a total of 31 articles. Clinical efficacy, patient-reported outcomes, and safety data were in 6 placebo-controlled trials (8 articles), 6 active-controlled trials, and 16 observational studies (17 articles). Data on health economic outcomes were provided in one of the clinical trials, in two of the observational studies, and in one specific cost-analysis publication. This review demonstrated that the routine use of abobotulinumtoxinA in CD is well-established, effective, and generally well-tolerated, with a relatively low cost of treatment.
View Full-Text
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 168 KiB)
MDPI and ACS Style
Fasano, A.; Paramanandam, V.; Jog, M. Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review. Toxins 2020, 12, 470. https://doi.org/10.3390/toxins12080470
AMA Style
Fasano A, Paramanandam V, Jog M. Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review. Toxins. 2020; 12(8):470. https://doi.org/10.3390/toxins12080470
Chicago/Turabian StyleFasano, Alfonso; Paramanandam, Vijayashankar; Jog, Mandar. 2020. "Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review" Toxins 12, no. 8: 470. https://doi.org/10.3390/toxins12080470
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit